Role of HPV testing in the follow-up of women treated for cervical dysplasia
- PMID: 20012636
- DOI: 10.1007/s00404-009-1316-5
Role of HPV testing in the follow-up of women treated for cervical dysplasia
Abstract
Purpose: The aim of study was to investigate factors predicting persistence or relapse of disease after cervical conisation for high-grade squamous intraepithelial lesions (CIN 2 or 3).
Methods: The study involved 78 women with high-grade squamous intraepithelial lesions, conservatively treated with loop electroexcision procedure for cervical conisation and subsequent with CO(2) laser-vaporisation of the cervical bed. Histological specimens were totally included and examined by an experienced pathologist. To evaluate the efficacy of treatment, the patients were examined with colposcopy and Pap smear 4 months after surgery and with PCR to search for and genotyping of HPV, 10 months after treatment.
Results: During the post-treatment follow-up, the cytologic examination showed persistent/relapsing disease in six patients (7.6%). In only 1 case, the deep margin of the cone was considered positive for CIN (16%).Ten months after treatment, viral typing revealed the persistence of high-risk HPV in all of these patients. Conversely, the viral follow-up of the other 72 patients without persisting/relapsing disease after treatment disclosed low-risk HPV genotypes in 6 cases, high-risk HPV in 2 cases (2.7%), whereas 7 cases had positive margins for CIN (9.7%). The risk of persistence and relapse of CIN in the group with positive margins was not statistically significant (P = 0.87), whereas it was in the group with HR-HPV positive (P = 0.000048).
Conclusion: HPV testing is the most sensitive mean of identifying persistence or relapse early and is therefore capable of optimising follow-up after the treatment of high-grade CIN.
Similar articles
-
Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.Int J Cancer. 2017 Jul 1;141(1):8-23. doi: 10.1002/ijc.30623. Epub 2017 Feb 27. Int J Cancer. 2017. PMID: 28124442 Free PMC article.
-
Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.Gynecol Oncol. 2007 Jul;106(1):170-6. doi: 10.1016/j.ygyno.2007.03.016. Epub 2007 May 4. Gynecol Oncol. 2007. PMID: 17481701
-
Prognostic significance of high-risk HPV persistence after laser CO2 conization for high-grade CIN: a prospective clinical study.Eur J Gynaecol Oncol. 2008;29(4):378-82. Eur J Gynaecol Oncol. 2008. PMID: 18714574 Clinical Trial.
-
[Clinical aspects of HPV-16/18 associated cervical lesions].Geburtshilfe Frauenheilkd. 1990 Feb;50(2):106-9. doi: 10.1055/s-2007-1026444. Geburtshilfe Frauenheilkd. 1990. PMID: 2156746 German.
-
High-grade cervical intraepithelial neoplasia, human papillomavirus and factors connected with recurrence following surgical treatment.Clin Exp Obstet Gynecol. 2008;35(4):242-7. Clin Exp Obstet Gynecol. 2008. PMID: 19205435 Review.
Cited by
-
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.Viruses. 2018 Dec 19;10(12):729. doi: 10.3390/v10120729. Viruses. 2018. PMID: 30572620 Free PMC article. Review.
-
Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.Int J Cancer. 2017 Jul 1;141(1):8-23. doi: 10.1002/ijc.30623. Epub 2017 Feb 27. Int J Cancer. 2017. PMID: 28124442 Free PMC article.
-
The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.Gynecol Oncol. 2014 Mar;132(3):767-79. doi: 10.1016/j.ygyno.2013.12.040. Epub 2014 Jan 7. Gynecol Oncol. 2014. PMID: 24412508 Free PMC article.
-
Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.J Gynecol Oncol. 2016 Jan;27(1):e3. doi: 10.3802/jgo.2016.27.e3. Epub 2015 Oct 8. J Gynecol Oncol. 2016. PMID: 26463429 Free PMC article.